Itaconate promotes an unexpected tumor immune escape mechanism

IF 48.8 1区医学 Q1 CELL BIOLOGY

Cancer Cell Pub Date : 2024-11-14 DOI:10.1016/j.ccell.2024.10.011

Lara Haase, Christian Frezza

引用次数: 0

Abstract

Itaconate is a metabolite produced by macrophages upon infection and acts as an antimicrobial molecule. In this issue of Cancer Cell, Lin et al. found that itaconate produced by tumor-associated macrophages is taken up by cancer cells via the transporter solute carrier family 13 member 3 (SLC13A3), promoting resistance to immune checkpoint inhibitors.

查看原文本刊更多论文

伊塔康酸促进一种意想不到的肿瘤免疫逃逸机制

伊他康酸是巨噬细胞在感染时产生的一种代谢产物，是一种抗菌分子。在本期《癌细胞》（Cancer Cell）杂志上，Lin 等人发现，肿瘤相关巨噬细胞产生的伊他康酸可通过转运体溶质运载家族 13 成员 3（SLC13A3）被癌细胞吸收，从而促进癌细胞对免疫检查点抑制剂产生抗药性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Cell 医学-肿瘤学

CiteScore

55.20

自引率

1.20%

发文量

179

审稿时长

4-8 weeks

期刊介绍： Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.